Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Breast Cancer: early-phase trial registry
6 of 18 indexed Stage III Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 6 currently recruiting · #953 of 28,707 conditions by registered trial count
Stage III Breast Cancer: 18 US clinical trials tracked, 6 recruiting.
Stage III Breast Cancer is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 4 of these trials.
Enrollment posture brief
Registry condition stage-iii-breast-cancer
OPEN 6 | RECR 33% | LATE 2 | EARLY 9 | RANK #953 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Stage III Breast Cancer lists 6 open slots (33% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Breast Cancer is recruiting below its size-band peers.
6 of 18 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Breast Cancer research.
Dana-Farber Cancer Institute accounts for 4 of 18 trials (22.2%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 62 among the 18 trials that report a genuine target (sentinel values excluded). 12 of those (66.7%) plan for fewer than 100 participants.
-
Stage III Breast Cancer research is mostly interventional.
18 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Dana-Farber Cancer Institute
NCT05535192
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Wake Forest University Health Sciences
NCT05595577
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT04553770
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07042581
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Barbara Ann Karmanos Cancer Institute
NCT07095114
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ECOG-ACRIN Cancer Research Group
NCT02445391
MARGetuximab Or Trastuzumab (MARGOT)
Dana-Farber Cancer Institute
NCT04425018
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
NCT02326974
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
NCT04584255
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NCT04007770
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
University of Washington
NCT02157051
Researching the Effect of Exercise on Cancer
Memorial Sloan Kettering Cancer Center
NCT04589468
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
Ask Questions (ASQ):Implementation of a Communication Intervention
Barbara Ann Karmanos Cancer Institute
NCT05025748
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
George W. Sledge Jr.
NCT03364348
Living Well After Breast Surgery
University of Texas at Austin
NCT03834532
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03102866
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Breast Cancer page
18 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Stage III Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Stage III Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Breast Cancer condition card totals 18 registered trials; most-linked intervention Pertuzumab; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.